{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:19:02Z","timestamp":1788545942667,"version":"build-2803163510"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Several drugs gained market authorization based on the demonstration of improved progression-free survival (PFS), adopted as a primary endpoint in Phase 3 clinical trials. In addition, an increasing number of drugs have been granted accelerated approval, and sometimes regular approval, by the main regulatory agencies based on the evaluation of the overall response rate in Phase 1 and 2 clinical trials. However, while the overall survival is an unbiased measure of drug efficacy, these outcomes rely on the assessment of radiological images and patients\u2019 categorization using standardized response criteria. The evaluation of these outcomes may be influenced by subjective factors, particularly when the analysis is performed locally. In fact, blinding of treatment is not always possible in modern oncology trials. Therefore, a blinded independent central review is often adopted to overcome the problem of expectation bias associated with local investigator assessments. In this regard, we have recently observed that local investigators tend to overestimate the overall response rate in comparison to central reviewers in Phase 2 clinical trials, whereas we did not find any significant evaluation bias between local investigators and central reviews when considering progression-free survival in both Phase 2 and 3 trials. In the present article, we have tried to understand the reasons behind this discrepancy by reviewing the available evidence in the literature. In addition, a further analysis of Phase 2 and 3 clinical trials that included the evaluation of both endpoints showed that local investigators significantly overestimate overall response rates compared to blinded independent central reviews in uncontrolled oncology trials.<\/jats:p>","DOI":"10.3389\/fphar.2022.858354","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:57:55Z","timestamp":1652684275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Cinzia","family":"Dello Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1634\/theoncologist.2009-0261","article-title":"Blinded Independent central Review of the Progression-free Survival Endpoint","volume":"15","author":"Amit","year":"2010","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ejca.2011.02.013","article-title":"Blinded Independent central Review of Progression in Cancer Clinical Trials: Results from a Meta-Analysis","volume":"47","author":"Amit","year":"20111990","journal-title":"Eur. J. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in Relapsed or Refractory Richter Syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","article-title":"Objective Response Rate Assessment in Oncology: Current Situation and Future Expectations","volume":"11","author":"Aykan","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as First-Line Treatment in Cisplatin-Ineligible Patients with Locally Advanced and Metastatic Urothelial Carcinoma: a Single-Arm, Multicentre, Phase 2 Trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"v602","DOI":"10.1093\/annonc\/mdz260","article-title":"Results of the ASCEND-7 Phase II Study Evaluating ALK Inhibitor (ALKi) Ceritinib in Patients (Pts) with ALK+ Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain","volume":"30","author":"Chow","year":"2019","journal-title":"Ann. Oncol."},{"key":"B10","unstructured":"2012"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A Systematic Review of Meta-Analyses Assessing the Validity of Tumour Response Endpoints as Surrogates for Progression-free or Overall Survival in Cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.21037\/atm.2020.03.118","article-title":"Looking for a Better Measure of the Benefit in Clinical Trials: a Never-Ending Journey","volume":"8","author":"Daniele","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B13","first-page":"1121","article-title":"Clinical Endpoints in Oncology - a Primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00228-020-02895-z","article-title":"A Comparison between the Assessments of Progression-free Survival by Local Investigators versus Blinded Independent central Reviews in Phase III Oncology Trials","volume":"76","author":"Dello Russo","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/jcph.1790","article-title":"Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials","volume":"61","author":"Dello Russo","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel with Placebo Plus Paclitaxel as First-Line Treatment for Metastatic Breast Cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2008.16.1711","article-title":"Blinded Independent Central Review of Progression-free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?","volume":"26","author":"Dodd","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II Study of Copanlisib, a PI3K Inhibitor, in Relapsed or Refractory, Indolent or Aggressive Lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in Advanced Clear-cell Renal-Cell Carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized Phase II Trial of First-Line Treatment with Sorafenib versus Interferon Alfa-2a in Patients with Metastatic Renal Cell Carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons Learned from Independent Central Review","volume":"45","author":"Ford","year":"20091990","journal-title":"Eur. J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-Resistant Ovarian Cancer: A Multicenter, Randomized, Controlled, Open-Label Phase 3 Study (CORAIL)","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B25","volume-title":"Cancer Today. International Agency for Research on Cancer","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2020.12.004","article-title":"Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma: Primary Results from the Randomized Phase III IMspire170 Study","volume":"32","author":"Gogas","year":"2021","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3978\/j.issn.2304-3865.2014.05.08","article-title":"The Changing World of Cancer Drug Development: The Regulatory Bodies' Perspective","volume":"3","author":"Gravanis","year":"2014","journal-title":"Chin. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A Systematic Review of Trial-Level Meta-Analyses Measuring the Strength of Association Between Surrogate End-Points and Overall Survival in Oncology","volume":"106","author":"Haslam","year":"20191990","journal-title":"Eur. J. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jjco\/hyx045","article-title":"Ceritinib in Patients with Advanced, Crizotinib-Treated, Anaplastic Lymphoma Kinase-Rearranged NSCLC: Japanese Subset","volume":"47","author":"Hida","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13244-021-00976-w","article-title":"RECIST 1.1 and Lesion Selection: How to deal with Ambiguity at Baseline?","volume":"12","author":"Iannessi","year":"2021","journal-title":"Insights Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/cas.13438","article-title":"Efficacy and Safety of Trametinib in Japanese Patients with Advanced Biliary Tract Cancers Refractory to Gemcitabine","volume":"109","author":"Ikeda","year":"2018","journal-title":"Cancer Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in Patients with Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-small-cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A Phase II Study of Trastuzumab Emtansine in Patients with Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-021-00389-3","article-title":"Synthetic Biomarkers: a Twenty-First Century Path to Early Cancer Detection","volume":"21","author":"Kwong","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0b013e3181b9c5ec","article-title":"Progression-free Survival: Gaining on Overall Survival as a Gold Standard and Accelerating Drug Development","volume":"15","author":"Lebwohl","year":"2009","journal-title":"Cancer J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): a Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase II KEYNOTE-100 Study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab versus Sunitinib in Renal Cell Carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and Efficacy of Crizotinib in Patients with Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial","volume":"14","author":"Michels","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without Avelumab Followed by Avelumab Maintenance versus Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jtho.2019.11.006","article-title":"Final Overall Survival and Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients with ALK-Rearranged NSCLC","volume":"15","author":"Nishio","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus Chemotherapy in Crizotinib-Pretreated Anaplastic Lymphoma Kinase (ALK)-positive Non-small-cell Lung Cancer: Results from the Phase III ALUR Study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e055488","DOI":"10.1136\/bmjopen-2021-055488","article-title":"Interventions to Improve Early Cancer Diagnosis of Symptomatic Individuals: A Scoping Review","volume":"11","author":"Okoli","year":"2021","journal-title":"BMJ open"},{"key":"B47","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and Safety of Copanlisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma","volume":"5","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","article-title":"Progression-free Survival Is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumour Clinical Trials","volume":"136","author":"Pasalic","year":"20201990","journal-title":"Eur. J. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance Therapy with Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care after Induction Therapy with Pemetrexed Plus Cisplatin for Advanced Non-squamous Non-small-cell Lung Cancer (PARAMOUNT): a Double-Blind, Phase 3, Randomised Controlled Trial","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III Marianne Study","volume":"35","author":"Perez","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2017.11.023","article-title":"Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens","volume":"73","author":"Perez-Gracia","year":"2018","journal-title":"Eur. Urol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II Trial of Atezolizumab as First-Line or Subsequent Therapy for Patients with Programmed Death-Ligand 1-Selected Advanced Non-small-cell Lung Cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab Alone or in Combination with Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): an Open-Label, Three-Arm, Randomised, Phase 3 Study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","article-title":"Dacomitinib versus Erlotinib in Patients with Advanced-Stage, Previously Treated Non-small-cell Lung Cancer (ARCHER 1009): a Randomised, Double-Blind, Phase 3 Trial","volume":"15","author":"Ramalingam","year":"2014","journal-title":"Lancet Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab Plus Bevacizumab versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): a Multicentre, Open-Label, Phase 3, Randomised Controlled Trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ejca.2014.05.024","article-title":"Progression-free Survival as an End-point in Solid Tumours-Perspectives from Clinical Trials and Clinical Practice","volume":"50","author":"Robinson","year":"20141990","journal-title":"Eur. J. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","article-title":"Capecitabine Plus Oxaliplatin (XELOX) versus 5-fluorouracil\/folinic Acid Plus Oxaliplatin (FOLFOX-4) as Second-Line Therapy in Metastatic Colorectal Cancer: a Randomized Phase III Noninferiority Study","volume":"19","author":"Rothenberg","year":"2008","journal-title":"Ann. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/nejmoa2027187","article-title":"& CROWN Trial Investigators First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomised, Open-Label, Controlled, Phase 3 Trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00277-019-03739-2","article-title":"Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"98","author":"Spicka","year":"2019","journal-title":"Ann. Hematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A. Cancer J. Clin."},{"key":"B65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdp478","article-title":"Influence of an Independent Review Committee on Assessment of Response Rate and Progression-free Survival in Phase III Clinical Trials","volume":"21","author":"Tang","year":"2010","journal-title":"Ann. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"B67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus Investigator's Choice in Relapsed or Refractory Mantle Cell Lymphoma (MCL-002; SPRINT): a Phase 2, Randomised, Multicentre Trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","article-title":"Phase 1\/2 Study of Ceritinib in Chinese Patients with Advanced Anaplastic Lymphoma Kinase-Rearranged Non-small Cell Lung Cancer Previously Treated with Crizotinib: Results from ASCEND-6","volume":"150","author":"Wu","year":"2020","journal-title":"Lung Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-small-cell Lung Cancer (ARCHER 1050): a Randomised, Open-Label, Phase 3 Trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e017240","DOI":"10.1136\/bmjopen-2017-017240","article-title":"Systematic Bias Between Blinded Independent Central Review and Local Assessment: Literature Review and Analyses of 76 Phase III Randomised Controlled Trials in 45 688 Patients with Advanced Solid Tumour","volume":"8","author":"Zhang","year":"2018","journal-title":"BMJ Open"},{"key":"B72","doi-asserted-by":"publisher","first-page":"481","DOI":"10.21037\/atm.2017.11.24","article-title":"Evaluation Bias in Objective Response Rate and Disease Control Rate Between Blinded Independent Central Review and Local Assessment: A Study-Level Pooled Analysis of Phase III Randomized Control Trials in the Past Seven Years","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:58:01Z","timestamp":1652684281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.858354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":72,"alternative-id":["10.3389\/fphar.2022.858354"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.858354","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"858354"}}